Q4 2025 Zydus Lifesciences Ltd Earnings Call Transcript
Key Points
- Zydus Lifesciences Ltd (BOM:532321) reported a strong double-digit growth in both revenue and operating profitability for FY25, with consolidated revenues up 19% year-on-year.
- The US business showed robust performance with double-digit growth, driven by volume expansion and successful new product launches.
- The Branded Formulations business in India outpaced market growth, supported by healthy volume growth and new product introductions.
- The Consumer Wellness business achieved industry-leading double-digit growth, with significant contributions from the Personal Care and Food & Nutrition segments.
- Digitalization and efficiency enhancement measures improved profitability by 50 to 70 basis points, with expectations for continued improvements.
- The company faces ongoing litigation related to Mirabegron, with the next trial scheduled for February 2026, which could impact future sales.
- There is a noted price erosion in the US market for Revlimid, which may affect profitability.
- The company anticipates a decrease in EBITDA margins for FY26 to around 26%, down from 30% in FY25, due to increased R&D expenses and competitive pressures.
- The mesalamine franchise, while still relevant, has lost significant value due to increased competition.
- The company has taken impairments on certain products and goodwill, reflecting challenges in specific markets and product lines.
Ladies and gentlemen, good day, and welcome to Zydus Life Sciences earnings conference call for the fourth-quarter FY25 ended March 31, 2025. I now hand over the conference to Mr. Ganesh Nayak for opening remarks. Thank you, and over to you, sir.
Good evening, ladies and gentlemen. It's my pleasure to welcome you all to our post results teleconference for the fourth quarter and the financial year ended March 31, 2025. For today's call, we have with us Dr. Sharvil Patel, Managing Director; Mr. Nitin Parekh, Chief Financial Officer; Mr. Tushar Shroff, President, Corporate Finance; Mr. Arvind Bothra, Head of Investor Relations; and Mr. Alok Garg, from the Managing Director's office.
To begin with, let me give you an overview of the performance for the year. I'm happy to inform you that we have ended the fiscal 2025 on a strong note. Overall, we delivered healthy growth during the year, in line with our expectations. On the profitability front, we exceeded our expectations with the highest ever
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
